Navigation Links
Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures
Date:7/23/2014

t program has involved over 3,000 people and offers over eight years of clinical experience with some patients.1 We look forward to discussing the data with the regulatory authorities and the scientific community."

Based on the results of the brivaracetam Phase 3 program, UCB plans to submit a New Drug Application to the US Food & Drug Administration (FDA) and a Marketing Authorization Application to the European Medicines Agency (EMA) in early 2015.

This Phase 3 study was a randomized, double-blind, placebo-controlled, multicentre, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam (100 and 200 mg/day) compared to placebo, over a 12-week treatment period, in 768 randomized focal epilepsy patients (aged 16 to 80 years) with partial-onset seizures, not fully controlled despite treatment with one or two concomitant AEDs.2,7 The primary endpoint for the European regulatory authorities is the 50% responder rate for partial-onset seizure frequency compared with placebo, over the treatment period standardized to a 28-day duration. The primary endpoint for the FDA is the percent reduction over placebo for partial-onset seizure frequency, over the treatment period standardized to a 28-day duration.2 Detailed data from this study will be submitted for presentation at upcoming epilepsy congresses and for publications in peer-reviewed journals.

About brivaracetam and the Phase 3 clinical development program Discovered and developed by UCB, brivaracetam is a highly selective synaptic vesicle protein 2A ligand.8,9

The phase 3 clinical development plan for brivaracetam consisted of the following studies:N01252: an evaluation of the efficacy and safety/tolerability of adjunctive brivaracetam 20, 50, and 100 mg/day compared with placebo over 12 weeks, in 399 randomized patients (greater than or equal to 16 to 70 yea
'/>"/>

SOURCE UCB
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Majority of Biotech/Pharma Employees Poised to Job Hunt
2. ZenCash Plucks Top Executives from Major DFW Brands
3. Accelerated Cure Project for Multiple Sclerosis Approved for Major Funding Award from Patient-Centered Outcomes Research Institute to Create MS Patient-Powered Research Network
4. Clinovo Rolls Out Major Enhancements for Open Source EDC ClinCapture at Outsourcing in Clinical Trials West Coast Conference
5. Verified Clinical Trials Stops Dual Enrollment in Clinical Trials in Major CNS Clinical Trials to Reduce Potential Adverse Events and Improve Data Quality
6. Major CRO Gives Top Ratings To Verified Clinical Trials To Stop Dual Enrollment In Clinical Trials On Late Phase Trial
7. Kibow Biotech Achieves Major Victory with Indias IPAB Decision to Uphold 2009 Product Patent
8. Sales Momentum Introduces 5 Payoffs to Asking Questions in Sales Calls in a White Paper - Mastering Major Account Selling
9. Dyadic International To Present At Two Major Conferences In December 2013
10. Sales Momentum Shares Three Common Pitfalls to Avoid When Developing Major Account Sales Strategies
11. The Blazing Diamond and the Quantum Jewel: Two Major Discoveries in Quick Succession
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... , Nov. 18, 2014 PDL BioPharma, ... that in connection with the acquisition of Durata Therapeutics, ... in connection with the termination of PDL,s credit agreement ... amount outstanding of $40 million, accrued interest, and prepayment ... entered into a structured financing transaction with Durata in ...
(Date:11/17/2014)... The new METTLER TOLEDO White Paper " Traceability ... becoming the first calibration laboratory in the world ... the microgram range. National Metrology Institutes (NMI's), private ... in nanotechnology applications will benefit from understanding the ... weights in the range of 0.05 mg to ...
(Date:11/15/2014)... Burlington, MA (PRWEB) November 13, 2014 ... today announced they were named one of the Boston ... among the Medium Sized Businesses in Massachusetts to receive ... Work’ honors employers who take care of their most ... The awards are presented annually, and are based on ...
(Date:11/15/2014)... Denver, Colorado (PRWEB) November 14, 2014 ... leading provider of proprietary, cloud-based analytics, and scientific ... results for the third quarter ended September 30, ... Quarter 2014 Highlights, ,     CannLabs – ... in Las Vegas, Nevada. ,     CannLabs – ...
Breaking Biology Technology:PDL BioPharma Announces Successful Conclusion of Debt Financing Agreement with Durata Therapeutics 2New White Paper on Microgram Weights Describes How to Achieve Traceable Measurement Down to 0.05 Milligrams 2Collaborative Consulting Honored with Boston Globe Top Places to Work 2014 2CannLabs Announces Third Quarter 2014 Results. 2CannLabs Announces Third Quarter 2014 Results. 3CannLabs Announces Third Quarter 2014 Results. 4CannLabs Announces Third Quarter 2014 Results. 5
... KANNAPOLIS, N.C. , May 26 The Immune ... Institute (DHMRI) today announced a collaboration to establish the Center ... H. Murdock Research Institute on the North Carolina Research Campus ... accelerate the discovery and development of new breakthrough treatments for ...
... 26 /PRNewswire-Asia-FirstCall/ -- NeoStem, Inc.,(NYSE Amex: NBS ) ("NeoStem" or the "Company"), ... the Company,s Chief Executive Officer, Robin Smith , M.D., will,ring the opening bell ... 9:30 a.m. ET on Thursday, May 27, 2010 . , ... "We are honored to be back at ...
... CHICAGO , May 26 Advanced ... ADLS), a biopharmaceutical company engaged in the discovery, development and ... oncology and respiratory diseases, today announced positive results from ... the efficacy of Restanza™ (cethromycin), its novel oral antibiotic, against ...
Cached Biology Technology:The Immune Tolerance Institute and David H. Murdock Research Institute Announce a Partnership Establishing a State of the Art Human Immune Monitoring Laboratory for Biomarker Discovery and Development 2The Immune Tolerance Institute and David H. Murdock Research Institute Announce a Partnership Establishing a State of the Art Human Immune Monitoring Laboratory for Biomarker Discovery and Development 3NeoStem to Ring Opening Bell at New York Stock Exchange on May 27, 2010 2NeoStem to Ring Opening Bell at New York Stock Exchange on May 27, 2010 3NeoStem to Ring Opening Bell at New York Stock Exchange on May 27, 2010 4Advanced Life Sciences Announces Restanza(TM) Shows Efficacy Against Malaria 2Advanced Life Sciences Announces Restanza(TM) Shows Efficacy Against Malaria 3Advanced Life Sciences Announces Restanza(TM) Shows Efficacy Against Malaria 4Advanced Life Sciences Announces Restanza(TM) Shows Efficacy Against Malaria 5
(Date:11/4/2014)... Medicine announced today that it is a Grand ... Bill & Melinda Gates Foundation. Laura Goetzl, ... Sciences; and Vice Chair of Research and Academic ... pursue an innovative global health and development research ... Neurodevelopment.", Grand Challenges Explorations (GCE) funds individuals worldwide ...
(Date:11/4/2014)... – (Nov. 4, 2014) – A majority of Madagascar,s ... that could have serious consequences for the rainforests they ... shows the positive impacts lemurs can have on rainforest ... their disappearance could have on the region,s rich biodiversity. ... have fruits eaten by lemurs. Lemurs in turn ...
(Date:11/3/2014)...  NeuroSigma ® , Inc. (NeuroSigma), a ... on commercialization of its non-invasive Monarch ... neurological and neuropsychiatric disorders, announced today that the ... Notice of Allowance for Mexican Patent Application No. ... and the Regents of the University of California ...
Breaking Biology News(10 mins):Temple University School of Medicine receives Grand Challenges Explorations grant 2Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... used chemical sleuthing to deduce what,s in fragranced consumer ... air wafting from household laundry vents. Findings, published online ... and Health, show that air vented from machines ... dryer sheet contains hazardous chemicals, including two that are ...
... Radiology,s flagship publication, the Journal of Vascular and ... arterial disease or PADcoinciding with the approach of September,s ... that Framingham Risk Score metrics (historically the gold standard ... enough to definitively say whether an individual may face ...
... from the University of Hawaii Cancer Center and The ... grant from the National Cancer Institute to develop novel ... joint analysis of gene expression and imaging data of ... Ph.D., a research scientist at the UH Cancer Center, ...
Cached Biology News:Scented laundry products emit hazardous chemicals through dryer vents 2Society of Interventional Radiology findings support PAD care; Legs For Life® gears up 2Society of Interventional Radiology findings support PAD care; Legs For Life® gears up 3Society of Interventional Radiology findings support PAD care; Legs For Life® gears up 4Society of Interventional Radiology findings support PAD care; Legs For Life® gears up 5Hawaii receives funding for liver cancer research 2
... negatively supercoiled DNA in presence of EDTA ... of supercoiling on transcription in vitro , ... the degree of supercoiling of naturally occurring DNA ... length by only one base-pair , Increasing ...
Kit Components: Anti-PARP LumiGLO Chemiluminescent Substrate Immunoblot Blocking Reagent Pyronin Y Reagent Goat Anti-Rabbit IgG, HRP conjugate Double-It Reagent Film Exposure Folders Autor...
... Deletion Kit for Kilo-Sequencing is designed to ... cloned into the multiple cloning sites (MCS) ... plasmid or phagemid vectors (pUC18/19). The kit ... in the target DNA, thereby progressively moving ...
Applications: Immunohistochemistry, ISH, FISH, CISH....
Biology Products: